Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study-Reference-Cited by-同舟云学术

Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study

Published:2021-04 Issue:4 Volume:35 Page:107839
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Basu Sanjay,Shao Hui,Luo Jing,Lipska Kasia,Suda Katie J.,Yudkin John S.

Funder

Leona M. and Harry B. Helmsley Charitable Trust

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference38 articles.

1. Effect of Patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus;Vijan;JAMA Intern Med,2014

2. Cost-related insulin underuse among patients with diabetes;Herkert;JAMA Intern Med,2019

3. Origins of the crisis in insulin affordability and practical advice for clinicians on using human insulin;Luo;Curr Diab Rep,2020

4. Clinician-level variation in three measures representing overuse based on the American Geriatrics Society choosing wisely statement;Rowe;J Gen Intern Med,2020

5. Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies;Hambling;Diabet Med,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Therapeutic Inertia in Type 2 Diabetes: Exploring Machine Learning-Based Scenario Simulation for Improving Short-Term Glycemic Control;Machine Learning and Knowledge Extraction;2024-02-14

2. Out of Pocket Spending on Insulin under $35 Copayment Caps;2022-12-21

3. Catastrophic Spending On Insulin In The United States, 2017–18;Health Affairs;2022-07-01

4. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis;The Lancet Diabetes & Endocrinology;2021-12